Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLFS NASDAQ:CVAC NASDAQ:NVAX NASDAQ:TLMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLFSBioLife Solutions$26.46+2.3%$23.10$19.10▼$29.55$1.27B1.78583,602 shs314,440 shsCVACCureVac$5.39+0.7%$5.43$2.37▼$5.72$1.21B2.53608,366 shs479,822 shsNVAXNovavax$7.90+1.4%$7.52$5.01▼$15.22$1.28B2.687.67 million shs5.43 million shsTLMDSOC Telemed$3.00$2.98$0.55▼$8.00$302.52M-1.441.28 million shsN/AMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLFSBioLife Solutions+2.28%+5.63%+25.46%+11.60%+7.21%CVACCureVac+0.75%+0.37%-1.10%+22.22%+91.81%NVAXNovavax+1.41%+5.76%+4.22%+6.04%-33.45%TLMDSOC Telemed0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLFSBioLife Solutions$26.46+2.3%$23.10$19.10▼$29.55$1.27B1.78583,602 shs314,440 shsCVACCureVac$5.39+0.7%$5.43$2.37▼$5.72$1.21B2.53608,366 shs479,822 shsNVAXNovavax$7.90+1.4%$7.52$5.01▼$15.22$1.28B2.687.67 million shs5.43 million shsTLMDSOC Telemed$3.00$2.98$0.55▼$8.00$302.52M-1.441.28 million shsN/AMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLFSBioLife Solutions+2.28%+5.63%+25.46%+11.60%+7.21%CVACCureVac+0.75%+0.37%-1.10%+22.22%+91.81%NVAXNovavax+1.41%+5.76%+4.22%+6.04%-33.45%TLMDSOC Telemed0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLFSBioLife Solutions 3.13Buy$31.2918.24% UpsideCVACCureVac 2.20Hold$6.8326.78% UpsideNVAXNovavax 2.13Hold$14.2980.83% UpsideTLMDSOC Telemed 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TLMD, CVAC, NVAX, and BLFS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/28/2025NVAXNovavaxHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.008/20/2025NVAXNovavaxBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform$9.00 ➝ $7.008/11/2025BLFSBioLife SolutionsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/8/2025BLFSBioLife SolutionsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.00 ➝ $32.007/22/2025BLFSBioLife SolutionsStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$30.007/22/2025NVAXNovavaxBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$10.00 ➝ $9.006/26/2025CVACCureVacUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Neutral$12.00 ➝ $5.506/17/2025NVAXNovavaxCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell$6.006/13/2025CVACCureVacJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold$7.00 ➝ $5.006/12/2025CVACCureVacCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeMarket Perform6/12/2025CVACCureVacCitizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLFSBioLife Solutions$82.25M15.41$0.12 per share215.98$7.52 per share3.52CVACCureVac$579.18M2.09$0.87 per share6.17$3.36 per share1.60NVAXNovavax$682.16M1.88N/AN/A($3.89) per share-2.03TLMDSOC Telemed$94.44M3.20N/AN/A$1.66 per share1.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLFSBioLife Solutions-$20.18M-$0.12N/AN/AN/A-5.39%0.16%0.14%11/11/2025 (Estimated)CVACCureVac$175.50M$0.965.61N/AN/A38.21%29.57%25.41%11/11/2025 (Estimated)NVAXNovavax-$187.50M$2.283.4698.750.1039.20%-142.33%28.65%11/11/2025 (Estimated)TLMDSOC Telemed-$50.54M-$0.57N/A∞N/A-53.52%-34.32%-20.96%N/ALatest TLMD, CVAC, NVAX, and BLFS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/21/2025Q2 2025CVACCureVac-$0.15-$0.30-$0.15-$0.30$4.27 million$1.41 million8/7/2025Q2 2025BLFSBioLife Solutions-$0.02-$0.33-$0.31-$0.33$23.71 million$25.42 million8/6/2025Q2 2025NVAXNovavax-$0.07$0.62+$0.69$0.62$149.19 million$239.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLFSBioLife SolutionsN/AN/AN/AN/AN/ACVACCureVacN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/ATLMDSOC TelemedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLFSBioLife SolutionsN/A4.433.45CVACCureVac0.056.176.16NVAXNovavax5.932.362.34TLMDSOC Telemed0.523.323.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLFSBioLife Solutions93.24%CVACCureVac17.26%NVAXNovavax53.04%TLMDSOC TelemedN/AInsider OwnershipCompanyInsider OwnershipBLFSBioLife Solutions2.20%CVACCureVac2.15%NVAXNovavax1.00%TLMDSOC Telemed6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLFSBioLife Solutions44047.90 million46.85 millionOptionableCVACCureVac880224.34 million219.52 millionOptionableNVAXNovavax1,990162.42 million160.80 millionOptionableTLMDSOC Telemed226100.84 million93.88 millionOptionableTLMD, CVAC, NVAX, and BLFS HeadlinesRecent News About These CompaniesThe Woman’s World Expert-Reviewed Glossary of GLP-1, Semaglutide and TelehealthNovember 14, 2024 | yahoo.comTrial reveals success of telemedicine-supported, village doctor–led approach to managing atrial fibrillationSeptember 2, 2024 | msn.comExplore the Innovations of Dr. Todd H. Lanman: An Influence in Spinal NeurosurgeryAugust 27, 2024 | usatoday.comComparative Studies in Society and HistoryAugust 24, 2024 | cambridge.orgCFrom science fiction to telemedicine: the surprising 150-year history of long-range medical treatmentAugust 9, 2024 | theconversation.comTTaipei Medical University Hospital successfully advances telemedicine, leveraging technology to provide comprehensive healthcareAugust 9, 2024 | digitimes.comDNavigating telemedicine and online doctors in Louisiana for more 'consumer-centric' careAugust 4, 2024 | nola.comNTelemedicine usage can have unexpected impact on rural communities' access to local careAugust 2, 2024 | msn.comCalifornia's Telemedicine Restrictions Are Forcing Rare Disease Patients To Travel Out of State for CareMay 23, 2024 | reason.comROne reader’s view | Cowlitz County Humane Society director urges expanding telemedicine for petsMay 10, 2024 | tdn.comTSociety ManMay 2, 2024 | bloodhorse.comBAccess to remote learning, telemedicine during extreme weather events ending for millionsMay 2, 2024 | nypost.comNTelemedicine Reduces Rehospitalization, Revascularization in Post-PCI ACS PatientsApril 7, 2024 | medscape.comMTelehealth Improves Hepatitis C Treatment in Patients With Opioid Use DisorderApril 4, 2024 | medpagetoday.comMUT Southwestern, Dallas telemedicine company partner on study to improve heart health in rural communitiesApril 4, 2024 | bizjournals.comMobile pet telehealth app expands offeringsApril 1, 2024 | dvm360.comDBill allowing telemedicine for pets awaits Gov. DeSantis' signatureMarch 11, 2024 | fox13news.comFDallas Trio To Bring ‘Specialists to Patients’ With Rural Cardiac Telemedicine PilotMarch 7, 2024 | dallasinnovates.comDJournal of the Royal Asiatic SocietyFebruary 29, 2024 | cambridge.orgC(LEAD) Gov't to fully allow telemedicine services in case of doctors' collective actionFebruary 19, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTLMD, CVAC, NVAX, and BLFS Company DescriptionsBioLife Solutions NASDAQ:BLFS$26.46 +0.59 (+2.28%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$26.46 +0.00 (+0.02%) As of 09/5/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.CureVac NASDAQ:CVAC$5.39 +0.04 (+0.75%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$5.36 -0.03 (-0.54%) As of 09/5/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Novavax NASDAQ:NVAX$7.90 +0.11 (+1.41%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$7.88 -0.03 (-0.32%) As of 09/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.SOC Telemed NASDAQ:TLMDSOC Telemed, Inc. provides acute care telemedicine services and technology to hospitals, health systems, physician groups, and government organizations in the United States. The company's Telemed IQ, a cloud-based software platform provides telemedicine solutions. Its telemedicine solutions include teleNeurology, telePulmonology, telePsychiatry, telecardiology, teleCritical Care (ICU), and other specialties. The company was founded in 2004 and is based in Herndon, Virginia. As of April 6, 2022, SOC Telemed, Inc. was taken private. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
